NDAINTRAVENOUSSOLUTION
Approved
Nov 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ULTRA-TECHNEKOW V4 (technetium tc-99m) by Curium Pharma is radiopharmaceutical activity [moa]. First approved in 1973.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ULTRA-TECHNEKOW V4 is a technetium tc-99m radiopharmaceutical diagnostic agent administered intravenously as a solution. It functions as a radioactive tracer for nuclear medicine imaging procedures. The drug enables physicians to visualize organ function and blood flow by detecting gamma radiation emitted by the tc-99m isotope.
LOE Approaching
As a 50+ year-old diagnostic product approaching LOE with moderate competitive pressure (30), the brand team is likely small and focused on retention and operational efficiency rather than growth-phase expansion.
Mechanism of Action
Radiopharmaceutical Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ULTRA-TECHNEKOW V4 offers stable, specialized expertise in diagnostic radiopharmaceutical manufacturing, regulatory compliance, and lifecycle management within a mature product portfolio. Career progression is best suited for professionals prioritizing operational excellence, regulatory knowledge, and supply chain stability over rapid commercialization growth.
Regulatory Affairs Specialist
Worked on ULTRA-TECHNEKOW V4 at Curium Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.